• NeuroSense held a meeting with Health Canada on potential regulatory pathways for PrimeC to treat ALS.
• Talks covered a proposed New Drug Submission strategy, supported by additional clinical, biomarker, long-term outcome data requested by Health Canada.
• An official Health Canada response is expected in Q3 2026, setting the next milestone for a potential Canadian filing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-066077), on June 08, 2026, and is solely responsible for the information contained therein.